OIPE IAP72 MAY 08 2006 PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/683,815
Filing Date	October 9, 2003
First Named Inventor	Arnon ROSENTHAL
Art Unit	1649
Examiner Name	K. Ballard
Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KAB	1.	US-2003/0147887-A1	08-07-2003	Wang et al.	
	2.	US-2003/0165496-A1	09-04-2003	Basi et al.	
	3.	US-2004/0038302-A1	02-26-2004	Nitsch et al.	
	4.	US-2004/0087777-A1	05-06-2004	Basi et al.	
	5.	US-2005/0130233-A1	06-16-2005	Nitsch et al.	
	6.	US-2005/0239169-A1	10-27-2005	Nitsch et al.	
	7.	US-2006/0057701-A1	03-16-2006	Rosenthal et al.	
	8.	US-2006/0057702-A1	03-16-2006	Rosenthal et al.	
	9.	US-5,225,539-A	07-06-1993	Winter	
	10.	US-5,545,566-A	08-13-1996	Growden et al.	
	11.	US-5,631,168-A	05-20-1997	Growdon et al.	
	12.	US-5,677,425-A	10-14-1997	Bodmer et al.	
	13.	US-5,962,463-A	10-05-1999	Nitsch et al.	
	14.	US-6,329,155-B1	12-11-2001	Nitsch et al.	
	15.	US-6,548,640-B1	04-15-2003	Winter	
KAB	16.	US-6,573,276-B2	06-03-2003	Hock et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
KAB	17.	WO-92/20373-A1	11-26-1992	Repligen Corporation		
	18.	WO-02/25279-A2, A3	03-28-2002	Evotec Neurosciences GMBH et al.		
	19.	WO-03/086310-A2, A3	10-23-2003	Ramot at Tel Aviv University Ltd.		
	20.	WO-2004/058184-A2	07-15-2004	Rinat Neuroscience Corp.		
	21.	WO-2004/095031-A1	11-04-2004	Universität Zürich		
KAB	22.	WO-2006/036291-A2	04-06-2006	Rinat Neuroscience Corp.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	23.	Armour, K.L. et al. (2003) "Differential Binding to Human FcγRIIa and FcγRIIb Receptors by Human IgG Wildtype and Mutant Antibodies," *Molecular Immunology* 40:585-593.	
	24.	Bach, J-F. et al. (1985). "Monoclonal Antibodies as Therapeutic Tools in Medicine" Chapter 22 *In* Handbook of Monoclonal Antibodies: Applications in Biology and Medicine, Ferrone, S. et al. eds., Noges Publications: Park Ridge: NJ, pp. 419-435.	

Examiner Signature		Date Considered	

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	K. Ballard
Sheet	2	of	3	Attorney Docket Number	514712001500

KAB	25.	Barbas III, C.F. et al. (2001). "Vector pComb3X, Figure 2.2" *In* Chapter 2 *In* Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 2.9-2.13.	
	26.	Bugelski, P.J. et al. (2000). "Preclinical Development of Keliximab, a Primatized ™ Anti-CD4 Monoclonal Antibody, in Human CD4 Transgenic Mice: Characterization of the Model and Safety Studies," *Human & Experimental Toxicology* 19:230-243.	
	27.	Canfield, S.M. et al. (June 1991). "The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the C_H2 Domain and Is Modulated by the Hinge Region," *J. Exp. Med.* 173:1483-1491.	
	28.	Chartier-Harlin, M.-C. et al. (2001). "A Promising Treatment For Alzheimer's Disease, or Can The Disease be Treated with the Disease?", *M/S Nouvelles Medicine Sciences* 17(4):523-524. (English Translation, three pages.)	
	29.	Das, P. et al. (September 17, 2003). "Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ $^{-/-}$ Knock-Out Mice," *J. Neurosci.* 23(24):8532-8538.	
	30.	De la Monte, S.M. (1999). "Molecular Abnormalities of the Brain in Down Syndrome: Relevance to Alzheimer's Neurodegeneration" *In* J. Neural Transm. Suppl., Lubec, G. eds., Springer-Verlag Wien: New York, NY 57:1-19.	
	31.	Deininger, M.H. et al. (December 15, 2002). "Aberrant Neuronal and Paracellular Deposition of Endostatin in Brains of Patients with Alzheimer's Disease," *J. Neurosci.* 22(24):10621-10626.	
	32.	Duncan, A.R. et al. (April 21, 1988). "The Binding Site for Clq on IgG," *Nature* 332:738-740.	
	33.	Genbank Accession No. CAA09181, created December 2, 1998, located at ~~<http://~~www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=3954885>, last visited October 19, 2005, two pages.	
	34.	Genbank Accession No. P01859, created July 21, 1986, located at ~~<http://~~www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=121043>, last visited October 19, 2005, four pages.	
	35.	Ghetti, B. et al. (2003). "Hereditary Prion Protein Amyloidoses," *Clin. Lab. Med.* 23(1):65-85.	
	36.	Gordon, M.N. et al. (2001). "Correlation Between Cognitive Deficits and Aβ Deposits in Transgenic APP+PS1 Mice," *Neurobiol. Aging* 22:377-385.	
	37.	Gordon, M.N. et al. (2002). "Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse," *Exp. Neurol.* 173:183-195.	
	38.	Hammarström, P. et al. (2003). "D18G Transthyretin is Monomeric, Aggregation Prone, and Not Detectable in Plasma and Cerebrospinal Fluid: A Prescription for Central Nervous System Amyloidosis?" *Biochemistry* 42(22):6656-6663.	
	39.	Harrington, C.R. et al. (1993). "Characterisation of an Epitope Specific to the Neuron-Specific Isoform of Human Enolase Recognised by a Monoclonal Antibody Raised Against a Synthetic Peptide Corresponding to the C-Terminus of β/A4-Protein," *Biochimica et Biophysica Acta* 1158(2):120-128.	
	40.	Hezareh, M. et al. (December 2001). "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type 1," *J. Virol.* 75(24):12161-12168.	
	41.	Holt, L.J. et al. (November 2003). "Domain Antibodies: Proteins for Therapy," *Trends in Biotechnology* 21(11):484-489.	
	42.	Idusogie, E.E. et al. (2000). "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," *J. Immunology* 164:4178-4184.	
↓	43.	Informal International Search Report mailed March 29, 2006, for PCT Application No. PCT/US03/32080 filed October 9, 2003, four pages.	
KAB	44.	Jefferis, R. et al. (1998). "IgG-Fc-Mediated Effector Functions: Molecular Definition of Interaction Sites for Effector Ligands and the Role of Glycosylation," *Immunological Reviews* 163:59-76.	

Examiner Signature		Date Considered	

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	K. Ballard
Sheet	3	of	3	Attorney Docket Number	514712001500

KAB	45.	Johnson, J.P. et al. (1985). "Monoclonal Antibodies and Melanomas" Chapter 18 *In* Handbook of Monoclonal Antibodies: Applications in Biology and Medicine, Ferrone, S. et al. eds., Noges Publications: Park Ridge: NJ, pp. 347-359.	
	46.	Kabawat, S.E. et al. (1985). "Monoclonal Antibodies in Diagnostic Pathology" Chapter 16 *In* Handbook of Monoclonal Antibodies: Applications in Biology and Medicine, Ferrone, S. et al. eds., Noges Publications: Park Ridge: NJ, pp. 293-328.	
	47.	Kahle, P.J. et al. (2002). "Hyperphosphorylation and Insolubility of α-Synuclein in Transgenic Mouse Oligodendrocytes," *EMBO Reports* 3(6):583-588.	
	48.	Lund, J. et al. (1996). "Multiple Interactions of IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains," *J. Immunology* 157:4963-4969.	
	49.	Morgan, A. et al. (October 1995). "The N-Terminal End of the C_H2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for C1q, FcγRI and FcγRIII Binding," *Immunology* 86(2):319-324.	
	50.	Nanus, D.M. et al. (December 2003). "Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen," *J. Urology* 170:S84-S89.	
	51.	Orgogozo, J-M. et al. (July 8, 2003). "Subacute Meningoencephalitis in a Subset of Patients with AD after Aβ42 Immunization," *Neurology* 61(1):46-54.	
	52.	Reddy, M.P. et al. (2000). "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4," *J. Immunology* 164:1925-1933.	
	53.	Redpath, S. et al. (1998). "The Influence of the Hinge Region Length in Binding of Human IgG to Human Fcγ Receptors," *Human Immunology* 59:720-727.	
	54.	Schultz, D.R. (1985). "Monoclonal Antibodies and Detection of Malignancies" Chapter 17 *In* Handbook of Monoclonal Antibodies: Applications in Biology and Medicine, Ferrone, S. et al. eds., Noges Publications: Park Ridge: NJ, pp. 329-346.	
	55.	Smith, D.H. et al. (May 2003). "Amyloid β Accumulation in Axons After Traumatic Brain Injury in Humans," *J. Neurosurg.* 98(5):1072-1077.	
	56.	Song, X. et al. (September 2002). "Fcγ Receptor I- and III-Mediated Macrophage Inflammatory Protein 1α Induction in Primary Human and Murine Microglia," *Infection and Immunity* 70(9):5177-5184.	
	57.	Tao, M-H. et al. (October 15, 1989). "Studies of Aglycosylated Chimeric Mouse-Human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," *J. Immunology* 143(8):2595-2601.	
	58.	Trojanowski, J.Q. et al. (2003). "Parkinson's Disease and Related α-Synucleinopathies Are Brain Amyloidoses," *Ann. N.Y. Acad. Sci.* 991:107-110.	
	59.	Wicher, K. et al. (1989). "Immunogenicity of Three Recombinant *Treponema pallidum* Antigens Examined in Guinea Pigs," *Int. Arch. Allergy Appl. Immunol.* 89:128-135.	
	60.	Wilcock, D.M. et al. (May 1, 2003). "Intracranially Administered Anti-Aβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation," *The Journal of Neuroscience* 23(9):3745-3751.	
↓	61.	Wright, A. et al. (1998). "Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells," *J. Immunol.* 160(7):3393-3402.	
KAB	62.	Yocum, D.E. et al. (July 1998). "Clinical and Immunologic Effects of a PRIMATIZED® Anti-CD4 Monoclonal Antibody in Active Rheumatoid Arthritis: Results of a Phase I, Single Dose, Dose Escalating Trial," *J. Rheumatol.* 25(7):1257-1262.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Kimberly Ballard/	Date Considered	07/12/2006

pa- 1059024